Literature DB >> 18602338

NKG2D ligands: key targets of the immune response.

Segundo González1, Alejandro López-Soto, Beatriz Suarez-Alvarez, Antonio López-Vázquez, Carlos López-Larrea.   

Abstract

NKG2D is an activating receptor expressed by NK and T cells. NKG2D ligands show a restricted expression in normal tissues, but they are frequently overexpressed in cancer and infected cells. The binding of NKG2D to its ligands activates NK and T cells and promotes cytotoxic lysis of the cells expressing these molecules. The mechanisms involved in the expression of the ligands of NKG2D play a key role in the recognition of stressed cells by the immune system and represent a promising therapeutic target for improving the immune response against cancer or autoimmune disease. In this review, we analyse the recent advances in understanding the regulation of NKG2D ligand expression and their therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602338     DOI: 10.1016/j.it.2008.04.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  101 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Authors:  Tong Zhang; Charles L Sentman
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

Review 3.  Revealing the molecular signatures of host-pathogen interactions.

Authors:  Chiea-Chuen Khor; Martin L Hibberd
Journal:  Genome Biol       Date:  2011-10-19       Impact factor: 13.583

4.  Conceptual aspects of self and nonself discrimination.

Authors:  Segundo Gonzalez; Ana Pilar González-Rodríguez; Beatriz Suárez-Álvarez; Alejandro López-Soto; Leticia Huergo-Zapico; Carlos Lopez-Larrea
Journal:  Self Nonself       Date:  2011-01-01

Review 5.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

Review 6.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 7.  Immunogenetics of the NKG2D ligand gene family.

Authors:  Masanori Kasahara; Shigeru Yoshida
Journal:  Immunogenetics       Date:  2012-07-29       Impact factor: 2.846

8.  Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells.

Authors:  Beatriz Suárez-Alvarez; Ramón M Rodriguez; Vincenzo Calvanese; Miguel A Blanco-Gelaz; Steve T Suhr; Francisco Ortega; Jesus Otero; Jose B Cibelli; Harry Moore; Mario F Fraga; Carlos López-Larrea
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

9.  Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells.

Authors:  Giuseppina Bonanno; Andrea Mariotti; Annabella Procoli; Maria Corallo; Giovanni Scambia; Luca Pierelli; Sergio Rutella
Journal:  BMC Immunol       Date:  2009-08-27       Impact factor: 3.615

10.  Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.

Authors:  Gal Markel; Rachel Seidman; Michal J Besser; Naama Zabari; Rona Ortenberg; Ronnie Shapira; Avraham J Treves; Ron Loewenthal; Arie Orenstein; Arnon Nagler; Jacob Schachter
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.